

**This item is the archived peer-reviewed author-version of:**

Assessment of forces in intradermal injection devices : hydrodynamic versus human factors

**Reference:**

Verwulgen Stijn, Beyers Koen, Van Mulder Timothi, Peeters Thomas, Truijen Steven, Dams Francis, Vankerckhoven Vanessa.- Assessment of forces in intradermal injection devices : hydrodynamic versus human factors  
Pharmaceutical research / American Association of Pharmaceutical Scientists - ISSN 0724-8741 - 35:6(2018), 120  
Full text (Publisher's DOI): <https://doi.org/10.1007/S11095-018-2397-2>  
To cite this reference: <https://hdl.handle.net/10067/1506390151162165141>

1    **Assessment of forces in intradermal injection devices: hydrodynamic**  
2    **versus human factors**

3    Running head: *Forces in ID injections: hydrodynamic vs human factors*

4    Stijn Verwulgen<sup>1,2,\*</sup>, Koen Beyers<sup>2,6</sup>, Timothi Van Mulder<sup>2,3,4</sup>, Thomas Peeters<sup>1</sup>,

5    Steven Truijen<sup>5</sup>, Francis Dams<sup>1</sup>, Vanessa Vankerckhoven<sup>2,4</sup>

6    Corresponding author:

7    Stijn Verwulgen

8    <sup>1</sup>Department of Product Development, Faculty of Design Sciences, University of  
9    Antwerp, Antwerp, Belgium

10   <sup>2</sup>Novasanis, Wijnegem, Belgium

11   <sup>3</sup> Department of Nursing and Midwifery, University of Antwerp, Wilrijk, Belgium

12   <sup>4</sup> Vaccine & Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium

13   <sup>5</sup> Department Rehabilitation Sciences and Physiotherapy, University of Antwerp,  
14   Wilrijk, Belgium

15   <sup>6</sup> Voxdale, Wijnegem, Belgium

16

17   \* Corresponding author:

18   [Stijn.verwulgen@uantwerpen.be](mailto:Stijn.verwulgen@uantwerpen.be)

19   Universiteit Antwerpen

20   Campus Mutsaard

21   Ambtmanstraat 1, 2000 Antwerpen

22   Tel: +32 (0)3 205 61 87

23

24 **Abstract**

25 **Purpose.** The force that has to be exerted on the plunger for administering a given  
26 amount of fluid in a given time, has an important influence on comfort for the subject  
27 and usability for the administrator in intradermal drug delivery. The purpose of this  
28 study is to model those forces that are subject-independent, by linking needle and  
29 syringe geometry to the force required for ejecting a given fluid at a given ejection  
30 rate.

- Stijn Verwulgen 27/2/18 10:17
- Deleted:** Needle and syringe geometry directly relates to the
- Stijn Verwulgen 27/2/18 10:16
- Deleted:** that can be administered at a given
- Stijn Verwulgen 27/2/18 10:16
- Deleted:** and with a given force. This
- Stijn Verwulgen 27/2/18 09:46
- Deleted:** both patient
- Stijn Verwulgen 27/2/18 10:13
- Deleted:** establish a method to
- Stijn Verwulgen 12/3/18 19:49
- Deleted:** inking
- Stijn Verwulgen 27/2/18 10:09
- Deleted:** predict the
- Stijn Verwulgen 27/2/18 10:12
- Deleted:** through a given needle in relation to the injection rate

31 **Material and methods.** We extend the well-known Hagen-Poiseuille formula to  
32 predict pressure drop induced by a fluid passing through a cylindrical body. The  
33 model investigates the relation between the pressure drop in needles and the theoretic  
34 Hagen-Poiseuille prediction and is validated in fifteen needles from 26G up to 33G  
35 suited for intradermal drug delivery. We also provide a method to assess forces

36 exerted by operators in real world conditions.

- Stijn Verwulgen 27/2/18 10:24
- Deleted:** that can be used in-vivo
- Stijn Verwulgen 27/2/18 10:24
- Deleted:** .

37 **Results.** The model is highly linear in each individual needle with R-square values  
38 ranging from 75% up to 99.9%. Ten out of fifteen needles exhibit R-square values  
39 above 99%. A proof-of-concept for force assessment is provided by logging forces in

40 operators in real life conditions.

- Stijn Verwulgen 27/2/18 10:25
- Deleted:** -vivo

41 **Conclusions.** The force assessment method and the model can be used to pinpoint  
42 needle geometry for intradermal injection devices, tuning comfort for subjects and  
43 usability for operators.

- Stijn Verwulgen 27/2/18 10:28
- Deleted:** with optimized

44  
45 **Keywords:** needle geometry; human factors; flow rate model; injection force;  
46 injection devices  
47 **Abbreviations:** intramuscularly (IM), intradermal (ID), subcutaneously (SC)

48

## 63 Introduction

64 The skin represents the largest organ of the human body (1). It consists of three  
65 layers: the epidermis, preventing chemicals and micro-organisms entering the body,  
66 the dermis playing a role in immunological surveillance, and the hypodermis or sub-  
67 cutis that consists mainly of subcutaneous fat providing insulation, restoring trauma  
68 and providing energy reserve (2-4). The skin is considered of particular interest for  
69 drug delivery due to its unique immunogenic properties and enhanced  
70 pharmacokinetics. To date vaccines are mainly administered intramuscularly (IM)  
71 with syringe and needle. Literature reports non-inferior immunogenic responses upon  
72 intradermal (ID) delivery (5, 6). Comparison of ID and SC administration in type 1  
73 diabetes showed a significant reduction of pain and superior pharmacokinetics. A  
74 more than 40% reduction in onset and 24% reduction in offset time could support  
75 closed loop therapy based on ID insulin administration (11, 12).

76 Traditionally, ID injections are mainly achieved via the Mantoux technique: a  
77 hypodermic needle is inserted almost parallel, at 5-10 degrees, into the subject's skin  
78 to assure that the needle outlet is located in the dermal zone (13). This requires  
79 training (14) and it is hard to exclude false-negative injections without bleeding and  
80 bruising (15) and is considered to be painful by the patient.

81 Micro-needle arrays are considered to be a promising technology for ID and trans-  
82 dermal drug delivery (16) (17), but are inherently vulnerable to damage caused by  
83 insertion forces or forces for drug injection which might run up to 20N or more (18).  
84 This can result in a high failure rate in micro needle based drug administration (19).  
85 Single needle-syringe systems can reduce failure rate, enhance repeatability of  
86 intradermal drug delivery and omit regulatory challenges faced by micro needle  
87 arrays. Single needle-syringe systems can facilitate testing and approval as an add-on

Vanessa Vankerckhoven 12/3/18 14:56

**Deleted:** A dose sparing effect has been addressed when ID delivery is used compared to IM delivery, e.g. an indication of 80% dose sparing in rabies vaccination (7) (8). Elderly vaccination has been demonstrated to be non-inferior for ID compared to IM delivery (5, 6, 9). Insulin was originally administered IM (10) and currently injected subcutaneously (SC).

Stijn Verwulgen 27/2/18 10:39

**Deleted:** Currently

Stijn Verwulgen 27/2/18 10:32

**Deleted:** but

Vanessa Vankerckhoven 12/3/18 14:58

**Deleted:** . Micro-needles

Vanessa Vankerckhoven 12/3/18 14:58

**Deleted:** . Insertion forces for micro-needle arrays

101 to existing vaccination technology (20). Adaptors that standardize ID injections offer  
102 the advantage to administer various drugs intra-dermally with a single types of  
103 standard tuberculin syringe (21, 22). Solutions have been launched in the life-science  
104 market to perform ID injections perpendicular to the subject's skin (23) (24) (16, 20),  
105 (25) (7). Perpendicular ID injections are promising new solutions since they allow  
106 targeting the dermis more precise and standardized, compared to the Mantoux  
107 technique, independent of the user's training experience. Also, single needle-syringe  
108 perpendicular ID delivery systems may drastically reduce pain compared to IM  
109 injections and decrease anxiety due to the short needle length (26). However the  
110 design of medical products is a complex process that requires many iterations linking  
111 usability factors with design requirements (27). In particular, the optimization of  
112 single needle perpendicular ID injections requires optimization for usability for the  
113 operator and comfort for the subject.  
114 A major usability factor is the force exerted by the operator to perform the injection  
115 (28). Injection rate, duration, volume to be injected and drug viscosity are parameters  
116 that directly relate to that force and hence usability of injection devices (29, 30) (31).  
117 These parameters also relate to comfort and acceptance of ID devices in subjects. In  
118 fact, pain merely relies on infusion rate, rather than on the total injected volume.  
119 Virtually painless injected volumes are possible up to 1ml at injection rates of  
120 0.1ml/min (32). On the other hand, subjects do not want to hold an auto injector on  
121 place for more than 15 seconds (33). Long injection times might also lead to  
122 hazardous situations. Evaluation in patients using an epinephrine auto injector  
123 revealed that only 16% of observed injections where performed along the  
124 manufacturer's instructions and 76% of failures are due to the patient's inability to  
125 hold the device in place to receive the required amount of substance (34).

Stijn Verwulgen 27/2/18 10:40

**Deleted:** standardize the Mantoux technique or to

Stijn Verwulgen 27/2/18 11:27

**Deleted:** S

Stijn Verwulgen 27/2/18 10:41

**Deleted:** The

Vanessa Vankerckhoven 12/3/18 14:59

**Deleted:** with single needle and perpendicular to the skin, needs

Stijn Verwulgen 27/2/18 11:25

**Deleted:** Adaptors that standardize ID injections offer the advantage to administer various drugs intra-dermally with a single type of standard tuberculin syringe (21, 22). To exploit all potential advantages of perpendicular ID drug delivery, new adaptors for single needle-syringe systems should be developed (20, 24). Activation and deactivation steps should be optimized for usability (26) in new ID injection devices.

Stijn Verwulgen 27/2/18 10:44

**Deleted:** nother

Stijn Verwulgen 27/2/18 10:51

**Deleted:** corresponding forces

Vanessa Vankerckhoven 12/3/18 14:53

**Deleted:** s

Stijn Verwulgen 27/2/18 11:16

**Deleted:** greatly influence

Vanessa Vankerckhoven 12/3/18 15:01

**Deleted:** For example

Vanessa Vankerckhoven 12/3/18 15:01

**Deleted:** For example, e

Stijn Verwulgen 27/2/18 13:05

**Formatted:** Font:Times

Stijn Verwulgen 27/2/18 13:05

**Formatted:** Font:Times

Stijn Verwulgen 27/2/18 13:05

**Formatted:** Font:Times

148 There is a current need to support the design of ID injection devices that are  
149 placed perpendicular to the subject's skin, for optimized efficacy, usability and safety.  
150 These desired outcomes depend on various parameters and constraints.  
151 Firstly, on one hand, the needle should be thin and sharp enough, not to induce pain or  
152 inaccuracies when perforating the subject's skin. At the same time, a sharp bevel  
153 results in a big outlet, increasing the risk of leakage, either exterior or into the  
154 subcutis. Also, the thinner the needle, the more force is to be exerted by operators for  
155 administering at the same rate. Secondly, on the other hand, the needle diameter  
156 should be big enough, to reduce injection time and forces required for injection. At  
157 the same time, a bigger diameter results in a bigger outlet, with similar risk on  
158 leakage. Bigger diameters thus result in smaller bevels, enhancing risk for pain when  
159 the needle perforates and inserts the subject's skin. Also, pain might increase with  
160 higher flow rate and higher viscosity. Thirdly, the length of the needle is bound to  
161 similar trade-offs. A fourth type of constraint is induced by new and promising  
162 applications in cell therapy. Therapeutic cells are preferably administered ID (35). As  
163 these drugs are highly viscous and their efficacy is generally highly sensitive to shear  
164 stresses, it is desirable to tune injection forces, ensuring functionality by controlling  
165 shear stress and optimizing usability by controlling injection forces.  
166  
167 Probably, the four type of constraints will conflict in the design of new ID injection  
168 devices, and therefore be subject to trade-off.  
169 These potential conflicting specifications merely depend on geometrical and  
170 mechanical specifications of needle and syringe, rather than on the physical and  
171 physiological characteristics of subjects' skin. Thus the question arises how to acquire  
172 forces require to inject a given substance at a given injection rate in function of needle

Stijn Verwulgen 27/2/18 13:06

Formatted: Line spacing: double

Stijn Verwulgen 27/2/18 13:05

Formatted: Font:Times

Stijn Verwulgen 27/2/18 13:15

Formatted: Left, Tabs:Not at 0,99 cm +  
1,98 cm + 2,96 cm + 3,95 cm + 4,94 cm  
+ 5,93 cm + 6,91 cm + 7,9 cm + 8,89  
cm + 9,88 cm + 10,86 cm + 11,85 cm

Stijn Verwulgen 27/2/18 13:05

Formatted: Font:Times

173 and syringe geometry. These data would allow tuning geometrical and physical  
174 needle-syringe parameters in single needle perpendicular ID injection devices,  
175 controlling injection rate, injection time and forces in function of intended  
176 application, usage and target group.  
177 We provide a model for the injection force of ID injection devices in function of  
178 syringe and needle geometry and drug viscosity. We also provide a method to assess  
179 actual forces in operators of site. Our model allows controlling injection rate and  
180 injection time. This can be used to optimize the usability in the design of new single  
181 needle ID injection devices.

182

## 183 Materials and methods

184 We provide a model for the hydrodynamic force from the fluid going through the  
185 syringe and needle. The model is constructed from hydrodynamic considerations and  
186 evaluated in 15 commercially available needles suited for intradermal injection,  
187 mounted in a commercially available 1ml syringe in a series of controlled  
188 experiments.

189 The friction force can be measured in a power bench or syringe pump. We also  
190 present a method to assess the actual total force exerted by operators of site. This is  
191 achieved by coupling force resistive sensors to a micro controller platform.  
192 Consequently, subject-specific tissue back-pressure and needle insertion force can be  
193 assessed by subtracting the hydrodynamic and friction forces from the total force  
194 measured.

### 195 1. Hydrodynamic model

196 We construct a model that links needle geometry, flow rate  $Q$ , dynamic viscosity  $\mu$ ,  
197 specific mass of a liquid  $\rho$  and injection force.

Stijn Verwulgen 27/2/18 13:05
<b>Formatted:</b> Font:Times
Stijn Verwulgen 27/2/18 15:10
<b>Formatted:</b> Font:Times
Stijn Verwulgen 27/2/18 15:10
<b>Formatted:</b> Font:Times
Stijn Verwulgen 27/2/18 15:10
<b>Formatted:</b> Font:Times
Stijn Verwulgen 27/2/18 11:08
<b>Deleted:</b> ... [1]
Stijn Verwulgen 27/2/18 11:01
<b>Deleted:</b> a
Stijn Verwulgen 12/3/18 20:12
<b>Deleted:</b> , together with
Stijn Verwulgen 27/2/18 14:18
<b>Deleted:</b> validate that

Stijn Verwulgen 27/2/18 14:52
<b>Deleted:</b> The total force for ID drug administration consists of four components: 1) the force of the needle penetrating the subject's skin (18), 2) force from tissue back-pressure due to injection of substance (29), 3) force from internal mechanics, e.g. in a classical syringe this only consists of friction between the plunger and housing and 4) hydrodynamic force from the fluid going through the syringe and needle.

Stijn Verwulgen 27/2/18 14:24
<b>Deleted:</b> to assess the hydrodynamic force

Stijn Verwulgen 27/2/18 14:27
<b>Deleted:</b> in-vivo

215 Both syringe and needle are modeled as cylindrical bodies. Let  $A$  be the area of a  
 216 cross-section of a cylindrical body,  $P$  the corresponding perimeter and  $D_h = \frac{4A}{P}$  the  
 217 hydraulic diameter of that cross-section. The velocity of a liquid flowing through that  
 218 body in function of location is denoted  $v$ . The average velocity of the liquid through a  
 219 cross-section is  $\bar{v} = \frac{\iint v \cdot dA}{A}$ . Further  $v_{max}$  denotes the maximal velocity in a cross-  
 220 section. The body we consider is vertically oriented in the gravity field with  $z$  the  
 221 vertical coordinate and  $g$  the gravity constant. The Reynolds number (dimensionless)  
 222 of the flow is  $Re = \frac{\rho v D_h}{\mu}$ . Let  $d_n$  be the internal diameter of the needle,  $l_n$  the length  
 223 of needle,  $v_n$  be the velocity of the fluid in the needle in function of location and let  
 224  $\bar{v}_n$  be the average velocity of the fluid in the needle. Concerning the syringe, let  $d_s$  be  
 225 the internal diameter of the syringe, which is taken to be equal to the diameter of the  
 226 plunger in the syringe, and let  $\bar{v}_s$  be the average velocity of the plunger in the syringe.  
 227 The considered fluid is incompressible. The following energy conservation between 2  
 228 cross-sections of a flow channel per unit of time holds when there are no transversal  
 229 pressure gradients in the cross-section:

$$-\Delta p \cdot Q = \rho g \Delta z \cdot Q + \Delta \iint \frac{1}{2} \rho v^2 v \cdot dA + \text{heat losses} \quad (1)$$

230 Mechanical components of this energy conservation law are already given in terms of  
 231 syringe, needle and fluid characteristics. Heat losses have to be further elaborated.  
 232 The term on the left side of (1) is the work exerted by the pressure on the liquid  
 233 flowing in and out of the control volume. On the right hand side of (1), the first term  
 234 is the increase in potential gravitational energy whereas the second term is the  
 235 increase of kinetic energy of the liquid flowing through the control volume. The third  
 236 term is the mechanical energy dissipated into heat. The kinetic energy correction  
 237 factor  $\alpha$  (see e.g. (36)) is defined as

$$\alpha = \frac{\iint \frac{1}{2} \rho v^2 \cdot v \, dA}{\frac{1}{2} \rho \bar{v}^2 Q}$$

238 With the definition and after dividing by the flow rate Q, equation (1) turns into:

$$-\Delta p = \rho g \Delta z + \Delta (\alpha \cdot \frac{1}{2} \rho \bar{v}^2) + \text{heat losses} \quad (2)$$

239 We further assume that the liquid in the syringe and needle is Newtonian with laminar

240 flow and without wall slips or hampering. For water injections ( $\mu = 1 \text{mPas}$ ) at 0.85

241 14  $\mu\text{l/s}$  and a 0.26 mm needle, the Reynolds number is 70. At 100  $\mu\text{l/s}$  and in a 0.13

242 mm needle the Reynolds number mounts to 1000. For more viscous liquids or drugs

243 in this window of flow rates and needle diameters the Reynolds numbers will even be

244 lower, which is well below 2000 which supports that our model is well in the laminar

245 flow area. For such flow in a long cylindrical body, the velocity profile over a cross-

246 section is parabolic:

247  $v = v_{max} \left(1 - \left(\frac{r}{R}\right)^2\right)$ . For parabolic velocity profiles in a circular cross-section, we

248 have

$$249 \quad \alpha = 2 \text{ and } \bar{v} = \frac{1}{2} v_{max}.$$

250 Starting from equation (2) for the syringe/needle geometry, the pressure drop from the

251 plunger to the exit section of the needle can be rewritten as

$$252 \quad -\Delta p = \rho g \Delta z + \Delta (\rho \bar{v}^2) + \text{heat losses} \quad (3)$$

253 The gravimetric term is for 100mm height difference of the order of 1000Pa and is

254 neglected. The kinetic term at the syringe plunger ( $\bar{v}_s$  limited to 100mm/s) is less than

255 100Pa and is neglected too. Thus equation (2) becomes

$$256 \quad |\Delta p| = \rho \bar{v}_n^2 + \text{heat losses} \quad (4).$$

257 The heat losses or viscous friction losses are composed of 1) the localized entrance

258 losses at the transition from the syringe to the needle and 2) the distributed tube losses

Stijn Verwulgen 12/3/18 20:49

Formatted: Font color: Auto

259 in the needle:

260 heat/friction losses =  $\Delta p_{entrance\ loss} + \Delta p_{tube\ loss}$  (5)

261 | Tube losses ~~are~~ given by the Darcy Weisbach equation (37):

262  $\Delta p_{tube\ loss} = f \cdot \left(\frac{L}{D_h}\right) \cdot \frac{1}{2} \rho \bar{v}_n^2$  (6),

263 with  $f$  the Darcy friction factor (dimensionless). For laminar flow of a Newtonian

264 liquid without wall slip it can be shown that  $f = \frac{64}{Re}$ . Applying this to a needle with

265 circular cross-section, equation (6) turns into the well-known Hagen –Poiseuille

266 equation to model pressure required to eject fluid through a cylindrical needle (33,

267 38):

268  $\Delta p_{tube\ loss} = \frac{128 \mu L}{\pi d_n^4} Q$  (7)

269 | The entrance losses in (5) are caused by a contracted flow in the entrance zone of the

270 | needle. Therefore, the flow requires temporarily a higher kinetic energy than the first

271 | term of (4), which is the kinetic energy downstream of this entrance zone. This excess

272 | kinetic energy is not completely recovered downstream of the entrance zone and this

273 | leads to a pressure drop, which is quadratic with the flowrate and is given by:

274  $\Delta p_{entrance\ loss} = k_e \cdot \frac{1}{2} \rho \bar{v}_{n,z}^2$

275 | with  $k_e$  the entrance loss coefficient (dimensionless) of the liquid flowing from the

276 | syringe into the needle. For circular cross-sections like a syringe needle geometry,

277 | these entrance losses are described analytically (39) and for  $Re > 10$  they compare to

278 | empirical work (40). Calculated values for  $k_e$  range from 0.3 for  $Re = 2000$  till 0.5 for

279 |  $Re = 100$ . Empirical numbers are 2 to 3 times larger (40). As the calculations do not

280 | take asymmetric or oscillating solutions into account,  $k_e$  is expected to be between 0,5

281 | and 1,5. We set use  $k_e = 1$ . For circular cross-sections and laminar flow where the

282 | kinetic correction factor  $a$  equals to 2, the entrance loss amounts to 25% up to 75% of

Stijn Verwulgen 12/3/18 20:43

Deleted: is

284 the kinetic energy in the flow. The cited values for  $k_e$  assume that the flow channel is  
285 longer than the distance over which the entrance effect takes place. For  $Re > 50$ , the  
286 ratio between the length  $L$  of the entrance effect and the diameter  $d$  of the flow  
287 channel is (39):

$$L/d = (0.05456Re - 0.5640 + 0.8476 \exp(-0.05869Re))$$

288 This shows that the entrance effect is expected to be in the order of 5 to 50 diameters  
289 for respectively  $Re = 100$  and  $Re = 1000$ , which is well below the length of the  
290 needles under study in this article.

291 The entrance losses in (5) is given by:

$$\Delta p_{\text{entrance loss}} = k_e \cdot \frac{1}{2} \rho \bar{v}_n^2 \quad (8),$$

293 with  $k_e$  the entrance loss coefficient (dimensionless) of the liquid flowing from the  
294 syringe into the needle. Since we have an incompressible fluid,

$$\bar{v}_s \cdot \frac{\pi d_s^2}{4} = \bar{v}_n \cdot \frac{\pi d_n^2}{4},$$

296 thus the force  $F_s$  on the plunger to overcome the pressure drop (4) is given by:

$$F_s = \frac{8 \pi d_s^4 \mu L}{d_n^4} \bar{v}_s + (2 + k_e) \cdot \frac{1}{2} \rho \frac{\pi d_s^6}{4 d_n^4} \bar{v}_s^2 \quad (9).$$

298 The total force  $F_{\text{exp}}$  to be exerted on the plunger to eject the liquid from the syringe is  
299 composed of friction of the plunger when moving in the syringe, denoted  $F_{\text{fric}}$ , and  
300 force to overcome pressure drop (9):

$$F_{\text{exp}} = F_{\text{fric}} + \frac{8 \pi d_s^4 \mu L}{d_n^4} \bar{v}_s + (2 + k_e) \cdot \frac{1}{2} \rho \frac{\pi d_s^6}{4 d_n^4} \bar{v}_s^2 \quad (10)$$

302 It will be verified experimentally how well the model by formulas (9) and (10) can  
303 predict the force on the plunger  $F_{\text{exp}}$  as a function of plunger velocity  $\bar{v}_s$  for  
304 commercially available needles suited for intra dermal injections, by controlling for  
305 the variables  $\bar{v}_s, d_s, d_n, l_n, \rho$  and  $\mu$ .

Stijn Verwulgen 12/3/18 21:37

Formatted: Font:Italic

Stijn Verwulgen 12/3/18 21:37

Formatted: Font:Italic

Stijn Verwulgen 12/3/18 21:26

Formatted: Font:12 pt, English (UK)

Stijn Verwulgen 12/3/18 21:03

Formatted: English (US)

306 2. Controlled experiment

307 A syringe adaptor was developed to administer fluid ID in a standardized way  
308 perpendicular to the skin. The adaptor is used in this study to control needle  
309 geometry. The adaptor is a particular realization of a platform (41), on which a realm  
310 of syringes with different dimensions and working principles can be built with needle  
311 dimensions varying between 26 and 34 G and protruding part of the needle, from the  
312 foot of the device ranging from 0.8mm up to 4mm, injecting a pre-defined fixed  
313 volume between 0.05cc and 0.3cc. The basic configuration consists of a housing with  
314 a needle suited for intradermal drug delivery, an activation mechanism and a skin  
315 penetration mechanism.

316 Fifteen commercially available needles (BD, EXEL, HSW and TSK) were selected to  
317 cover a variety of inner diameters  $d_n$  and lengths  $l_n$  and implemented in the housing.  
318 A regular syringe of 1 ml was used in the housing (HSW Soft-Ject Low Dead Space  
319 Luer Lock ). The syringe's inner diameter was assessed with a calliper with an  
320 accuracy of 0.02 mm. Each total needle length was assessed with the same calliper.  
321 Bevel length was assessed by an optical microscope as a tolerance measure for needle  
322 length, denoted z in Figure 1, right.

Stijn Verwulgen 27/2/18 15:31

Formatted: Font:Times

Stijn Verwulgen 27/2/18 15:31


Formatted: Font:Times

Stijn Verwulgen 27/2/18 15:31

Deleted: protruding needle length

324

325 *Figure 1: bevel measured with optical microscope (left) and geometrical definition of  
326 bevel subtracted from total length in needle length assessment.*



327 Needle diameter  $d_s$  was assessed through an optical microscope too. Needle types and  
328 geometric specifications as provided by manufacturers as well as assessed values are  
329 displayed in Table I.

330 The housing with needle and syringe was mounted to a force gauge (Electromatic  
331 ESM301) by dedicated designed and 3D printed support parts. Injection speed  $\bar{v}_s$  was  
332 controlled in the power bench. The power bench ensures a constant displacement and  
333 thereby returns applied force as a dependent variable. This force has an accuracy of  
334 0.2% according to the manufacturer's specifications, any eventual resulting error is  
335 neglected. Friction force of plunger moving in the syringe  $F_{fric}$  was assessed by  
336 moving the plunger in the syringe in an empty syringe at various speeds in the power  
337 bench. The same syringe and plunger was used in all experiments to minimize inter-  
338 syringe effects.

339 Force due to pressure drop through the needle was assessed by subtracting friction  
340 force from force assessed while ejecting fluid at the power bench.  
  
341 For the evaluation of the hydrodynamic model, in total 95 tests were performed, each  
342 test with 5 repetitions. In 90 tests, water was used as a liquid. Temperature varied  
343 between 15.4°C and 18.5°C. Viscosity was corrected for temperature. Five tests were  
344 performed on a water-glycerol mixture with viscosities of respectively 1.1 / 1.5 / 2.1 /  
345 2.9 / 4.3 mPas. In these five tests, a 32G-13mm length needle was used (number 14 in  
346 Table I).  
  
347 All experiments were preformed using a syringe with a diameter  $d_s = 4.67$  mm and  
348 velocities  $\bar{v}_s$  were set at 50, 125, 175, 200, 250 and 350 mm/min. Measured needle  
349 dimensions in Table I were used. In total, 15 types of needles were tested 5 times at  
350 these 6 flow rates. Results were analysed in SPSS.  
  
351 Dynamic viscosity was tuned by water-glycerol mixture. Newtonian behavior was  
352 controlled by Rheosense measuring device (Benelux Scientific). In all experiments,  
353 temperature was logged to control for eventual viscosity changes. Water-glycerol  
354 mixtures were tested at the same temperature ( $\pm 20^\circ\text{C}$ ) as those of the lab during the  
355 experiments. The vaccine HBVAXPRO (Sanofi-Pasteur) was tested to compare its  
356 behaviour to that of water-glycerol mixtures. All measurements were repeated five  
357 times in different shear rates: 2000, 5000, 10000, 15000 and 20000 /s.  
  
358 3. In vivo force assessment  
  
359 The effect of the needle gauge on force exerted by operators using the VAX-ID™  
360 syringe adaptor was assessed. The user scenario comprises the following steps: the  
361 operator fills the syringe by pulling up liquid from a vial; locks the prefilled syringe  
362 without needle in the housing; places the device on the receiver's skin thereby  
363 activating the injection mechanism and penetrating the skin; and injects the fluid by a

364 standard injection mechanism, that is by pushing the plunger, narrowing the syringe's  
365 reservoir and thus ejecting the fluid. In a pilot pre-clinical test, only operators are  
366 considered. Forces were assessed in 10 voluntary participants. Participants were asked  
367 to eject different volumes of demineralized water by pushing on the plunger of the  
368 syringe mounted in the housing of the syringe adaptor. No further instructions were  
369 given on how to perform the ejection. Fluid was ejected freely in the air without any  
370 injection in animal or human tissue, neither artificial substrate. The housing was  
371 equipped with a 26G and a 32G needle. A force -resistance sensor FSR-402 from  
372 Interlink was mounted on top of the plunger. It has a sensitive diameter of 13 mm and  
373 a sensing range from 0.2 N to 20 N with an accuracy of 0.1 N. A connection part was  
374 designed and 3D printed for solid mounting the sensor onto the top of the plunger and  
375 for distributing force exerted by the operator for stable and repeatable measurements.  
376 The set-up was wired to an Arduino microcontroller for read-out by a regular PC.

377

## 378 **Results**

### 379 Needle and syringe parameters

380 The inner diameter of the syringe was 4.67mm +/- 0.03 mm. Results of all needle  
381 measurement are compared with given specifications in Table I.

382 *Table I: Tested needles measured and manufacturer's parameters*

Needle #	Brand	Gauge	Spec. diam. (mm)	Spec. length (mm)	Measured Diam. (mm)	Measured length (mm)	Bevel length (mm)
1	BD	26G	0.26	10	0.269	15.651	1.49

Stijn Verwulgen 27/2/18 15:29  
Formatted Table

2	BD	26G	0.26	13	0.262	18.857	1.98
3	BD	26G	0.26	16	0.256	22.290	1.90
4	EXEL	27G	0.21	13	0.2160	19.424	1.81
5	HSW FINE	27G	0.21	30	0.212	38.482	1.74
6	HSW FINE	27G	0.21	40	0.208	44.411	1.77
7	HSW FINE	27G	0.21	42	0.213	48.139	1.99
8	HSW FINE	27G	0.21	50	0.210	56.369	1.95
9	EXEL	28G	0.184	20	0.203	27.130	1.39
10	EXEL	30G	0.159	13	0.158 0.157*	22.299	1.39
11	EXEL	30G	0.159	25	0.155	33.952	1.15
12	TSK	31G	0.133	13	0.138	18.635	1.15
13	TSK	32G	0.108	10	0.128	17.923	1.21
14	TSK	32G	0.108	13	0.127 0.130*	18.534	1.05
15	TSK	33G	0.108	13	0.104 0.105*	18.794	0.88

383 \*cross check measurement with electron microscope


384 The needle length of all evaluated needles was larger than the provided length

385 specifications: needles are prolonged internally in the needle hub, from 5 up to 10

386 mm.

387 Specifications were converted from Inch to mm. Most measured inner diameters of  
388 the needles correspond to the given specifications, except for the 32G and 28G  
389 needles that have larger actual diameters. The 32G-1mm needle has a diameter of  
390 0.127 mm with optical measurement what is just in the specified tolerance limit  
391 (0.108 mm +/- 0.019 mm).

392 Re-assessment with electron microscope yields 0.130mm what falls outside that  
393 tolerance limit. For the 28G needle the measured diameter is just within the tolerance  
394 limits. In Figure 2, a measurement of needle diameter is displayed for optical and  
395 electron microscope. Due to relative long bevels it was impossible to take a sharp  
396 image of the entire needle hole, perpendicular to the needle. However detailed partial  
397 electron-microscope images (Figure 2, right) indicate that inner wall might have high  
398 roughness and might be substantially non-cylindrically shaped.



399

400 Figure 2: optical assessment of needle diameter (left) and assessment with electron-  
401 microscope (middle and right) for a 33G-13 mm length needle

402 Friction force of plunger moving in the syringe  $F_{fric}$  was found to increase with  
403 increasing speed, although not linear. Table II shows results of average friction forces  
404 under 10 repeated measurements.

405 *Table II: friction force of plunger moving in the syringe at different speeds, controlled*  
406 *by the power bench.*

Injection speed (mm/min)	Friction force (SD) <i>in Newton</i>
50	0.561 (0.0722)
125	0.766 (0.0932)
175	0.829 (0.111)
200	0.852 (0.115)
250	0.902 (0.148)
350	1.014 (0.154)

407

408 Viscosity:


409 Both water and water-glycerol mixtures demonstrate Newtonian behaviour., i.e.  
410 viscosity remains substantially constant when changing the shear rate. HBVAXPRO  
411 exhibits non-Newtonian behaviour by shear thinning: the viscosity drops by  
412 increasing shear rate. *Consequently, the actual hydrodynamic forces could be smaller*  
413 *than the forces provide by our model. Results are displayed in Figure 3.*

Stijn Verwulgen 27/2/18 15:34

**Deleted:** -N

Stijn Verwulgen 27/2/18 15:54

**Formatted:** English (UK), Check spelling  
and grammar



*Figure 3: Viscosity in function of shear rate*

#### Evaluation of the proposed hydrodynamic model

The force measurements on the syringe plunger in the test bench are compared to results obtained from formula (10) after controlling for  $d_s$ ,  $d_n$ ,  $\bar{v}_s$ ,  $l_n$ ,  $\rho$  and  $\mu$ . Based on (39) we propose  $k_e = 1$  for the entrance loss coefficient. However, since the entrance loss  $k_e$  depends on the specific needle's hub geometry, we also evaluate our model for best fit for  $k_e$  for any individual needle.

In Figure 4 below, a regression of 90 data points (dotted line) is shown between the measured forces  $F_{exp} - F_{fric}$  on the vertical axis and the forces calculated using formula (9) on the horizontal axis.

Stijn Verwulgen 27/2/18 16:18

Formatted: Caption, Centered

Vanessa Vankerckhoven 12/3/18 14:49


Formatted: Font:Italic, English (US)

Stijn Verwulgen 27/2/18 15:55

**Deleted:** In total 95 tests were performed, each test with 5 repetitions. In 90 tests, water was used as a liquid. Temperature varied between 15.4°C and 18.5°C. Viscosity was corrected for temperature. Five tests were performed on a water-glycerol mixture with viscosities of respectively 1.1 / 1.5 / 2.1 / 2.9 / 4.3 mPas. In these five tests, a 32G-13mm length needle was used (number 14 in T ... [2]

Stijn Verwulgen 27/2/18 16:19

**Deleted:** these



437


438     *Figure 4: Measured forces on the vertical axis versus predicted forces on the*  
 439     *horizontal axis. Both units at horizontal and vertical axis are Newton (N).*

440     A regression line was calculated yielding


441                  $F_{exp} - F_{fric} = 0.91 F_s + 0.020 N$  ,

442     with  $R^2 = 95.5\%$  significant at the 0.001 level and the intercept of 0.020N is in a 95%  
 443     confidence interval around 0 (t-distribution). The intercept is thus not significantly  
 444     different from 0 (significance level  $p = 0.70$  ).

445     The correlation coefficients for the individual needle's regression lines are even much  
 446     closer to 1 (Figure 5 and Table III).




447



448

20



449

450 *Figure 5: Measured forces  $F_{exp} - F_{fric}$  on the vertical axis versus predicted forces  $F_s$  on*  
 451 *the horizontal axis for all types of needle. Units on both axis are Newton (N).*

452 *Numbers 1-15 refer to needle numbers in Table I*

453 Despite correlations of 10 needles are more than 99%, the slopes still vary from 0.55  
 454 to 1.21. This suggests that the assessment of individual needle geometry is prone to  
 455 error, whereas the formula (10) sufficiently models the behaviour for a given needle  
 456 with accurate geometrical parameters. This is supported by the result that each  
 457 individual intercept is in a 95% confidence interval around 0. Moreover, corrections  
 458 on individual diameters to explain slope variation, range between 0.000 and 0.032  
 459 mm. In 60% of all evaluated needle, these corrections are within a 10 micron  
 460 tolerance.

461 A disagreement between model and measurement can be observed at low plunger  
 462 force, see Figure 5, especially for 26G and 27G needles. This could possibly be

463 | contributed to enlargement of relative errors on force measurements.

464 Slope, intercept and correlations for individual needles with  $k_e = 1$  are displayed in  
465 Table III. The correction on the inner diameter  $\Delta d_n$  to achieve a slope of 1 is displayed  
466 in the most right column.

467 *Table III: Regression, slope a, intercept b and R<sup>2</sup> with  $F_{exp} - F_{fric} = aF_s + b$ , in  
468 function of needle geometry, and correction on diameter to provide a slope of 1*

Needle #	$d_n$ mm	$l_n$ mm	Slope a	Intercept $b(N)$	$R^2$	$\Delta d_n$ mm
1	0.270	15.7	0.70	0.033*	99.8%***	0.024
2	0.262	18.9	0.63	0.031*	94.5%***	0.032
3	0.256	22.3	0.81	-0.030*	80.9%***	0.014
4	0.216	19.2	0.57	0.152	97.9%***	0.032
5	0.212	38.4	0.93	-0.056*	97.3%***	0.004
6	0.209	44.6	0.91	0.043*	98.4%***	0.005
7	0.213	48.0	1.08	0.008*	99.8%***	-0.004
8	0.210	56.7	1.21	-0.043*	99.9%***	-0.010
9	0.203	27.1	0.55	0.002*	99.9%***	0.030
10	0.157	22.3	1.18	0.650*	99.7%***	-0.007
11	0.155	34.0	1.00	0.050*	99.9%***	0.000
12	0.138	18.6	0.64	0.088*	100.0%***	0.016
13	0.13	17.9	0.77	0.166	99.8%***	0.009
14	0.130	18.5	0.95	0.118*	99.8%***	0.002

15	0.105	18.8	0.96	0.023*	100.0%***	0.001
----	-------	------	------	--------	-----------	-------


469 \*\*\* significant at the 0.001 level \* within the 95% confidence interval

470 around 0 (*t*-distribution).

471 Finally we display the regression line for the 5 data points on the water glycol mixture  
 472 in Figure 6 with viscosities varying between 1.1 and 4.3 mPas. This line has a slope of  
 473 0.78, an intercept of 0.10N and an  $R^2 = 99.7\%$ , which yields the same conclusions.

474 Note that for drugs, non-Newtonian behaviour such as shear thinning for

475 | HBVAXPRO might influence results, [yielding lower actual forces](#).



476

477 | *Figure 6: verification of the hydrodynamic model in varying viscosity. Units on both*  
 478 *axis are Newton (N)*


479

480 | [Force assessment in human operators](#)


Stijn Verwulgen 27/2/18 16:25  
**Deleted:** In vivo f

482 A total of 10 untrained volunteers were recruited and asked to eject 0.7ml of saline  
483 solution with a 1mL SOFT-JECT Luer Lock syringe (Henke Sass Wolf) mounted in  
484 the VAX-ID™ adaptor two times: once equipped with a 26G needle and once with a  
485 32G needle. Ejection forces were logged using the FSR sensors coupled to the  
486 arduino platform. Results are displayed in Figure 7.

487



488



489

490 | *Figure 7: Time logs of forces exerted by non-educated operators with a 26 and 32G* ↗  
491 | *hypodermic needle respectively*

Stijn Verwulgen 27/2/18 16:26

Deleted: non-educated

Stijn Verwulgen 12/3/18 20:40

Formatted: Centered, Space After: 10 pt, Widow/Orphan control, Adjust space between Latin and Asian text, Adjust space between Asian text and numbers, Tabs:Not at 0,99 cm + 1,98 cm + 2,96 cm + 3,95 cm + 4,94 cm + 5,93 cm + 6,91 cm + 7,9 cm + 8,89 cm + 9,88 cm + 10,86 cm + 11,85 cm

493 **Discussion**

494 Difficult target groups such as children or elderly can benefit from ID drug delivery  
495 due to decreased pain, safety and ease of administration. In adults, a needle length of  
496 1mm is most suited for ID injection at the forearm (42). The Mantoux technique can  
497 target this depth by stretching the skin to insert a needle with upward tip in the  
498 upmost dermal tissue. The Mantoux technique dates from 1910 and to date is still  
499 used for e.g. tuberculin and/or HIV infection testing (43) by assessing the bleb  
500 visually for antigen reaction. It requires trained medical staff to perform and is limited  
501 in needle geometry: relatively large needles of 27 Gauge cause bruising and bleeding  
502 but reduce leakage and larger blebs, thereby requiring more training. Relatively small  
503 needles of 30 Gauge have more risk of leakage and administering less effective dose  
504 (15). Current developments aim to standardize ID injection to enhance reliability with  
505 solutions that inject substance perpendicular to the skin.

506 The total force for such ID drug administration consists of four components: 1) the  
507 force of the needle penetrating the subject's skin (18), 2) force from tissue back-  
508 pressure due to injection of substance (29), 3) force from internal mechanics, e.g. in a  
509 classical syringe this only consists of friction between the plunger and housing and 4)  
510 hydrodynamic force from the fluid going through the syringe and needle. By direct  
511 acquisition of the third and fourth component and by assessing the actual total force  
512 exerted by operators of site, an estimate of the sum of first and second component can  
513 be obtained by subtracting the third and fourth component from the actual  
514 measurement.

515 Needle dimensions for ID administration are subject to a trade-off. On one hand, thin  
516 needles and blunt beveled needles are preferred for reliably targeting the dermis at  
517 1mm depth without leakage exterior and into to the subcutis. Thin needles can induce

Stijn Verwulgen 12/3/18 20:41  
Deleted: A

Stijn Verwulgen 27/2/18 16:47  
Deleted: -

Vanessa Vankerckhoven 12/3/18 15:22  
Deleted: -

521 the possibility of self-administration (44). On the other hand, needle diameter should  
522 not be too small since higher force required to inject at the same rate might cause  
523 discomfort in operators and/or pain in subjects. An upper limit of 30N for injection  
524 force was recommended for manual injection into air (30). Also, the formulation of  
525 drug and in particular dynamic viscosity relates to bigger needle dimensions (31). Too  
526 high shear forces might also influence drug efficacy after administering through  
527 microneedles (45).

528 Tapered microneedles are developed in a trade off between enhanced flow rate and  
529 reduced infusion pain (46).

530 We provide a model for injection forces in cylindrically shaped syringes and needles.

531 Our model extends the well-known Hagen-Poiseuille law (38) and holds with  $R^2$   
532 >99% in 10 out of 15 needles, with a minimum  $R^2$  of 75%. This is remarkable in the  
533 light of potential perturbing parameters such as roughness or adhesive forces. We  
534 present a method to obtain injection forces *in vivo*. Preliminary experiments indicate  
535 that smaller needles result in bigger injection forces. The method needs to be tuned  
536 for robustness and calibrated off-site. Once this tuning is done, we have a method to  
537 link user requirements from subjects and operators to syringe and needle geometry,  
538 and pinpoint needle dimensions for ID injection devices that are most suited for  
539 operator and subject.

540 This might be achieved in three steps. Firstly, tissue back-pressure during ID injection  
541 should be mapped. This can be done by measuring the force during injection and  
542 simultaneously tracking the injection rate. The latter can be done by video recording  
543 and visually assessing the plunger moving down. Tissue back-pressure is then the  
544 difference between measured injection force and forces retrieved from injection rate  
545 through our model. Secondly, preferred forces and injection times should be mapped.

Stijn Verwulgen 27/2/18 16:55

Deleted: is

547 This can be done by inquiring both subjects and operators on what values they  
548 consider comfortable. Thirdly, knowledge on tissue back pressure and the present  
549 model could be used to select needles that are suitable for ID injections [in function of](#)  
550 [requirements for operator, subjects and intended applications.](#)

## 551 Conclusions

552 Needle and syringe geometry directly relates to the amount of fluid that can be  
553 administered at a given time and with a given force. The latter two parameters  
554 drastically influence comfort of both subject and operator in intradermal drug  
555 administration. In the current development of small needles suited for intradermal  
556 administration, much effort has gone into the design of the needle's shape.  
557 We have presented a model to predict the force to eject a given fluid through a given  
558 needle in function of injection rate. The first part of that force consists of the friction  
559 between plunger and syringe. The second part consists of hydrodynamic forces  
560 caused by the fluid going through the syringe and needle. The model extends the well-  
561 known Hagen-Poiseuille equation used to predict pressure drop induced by a fluid  
562 passing through a cylindrical body. The model is highly linear in each individual  
563 needle with R-square values ranging from 75% up to 99.9% and 2/3 of these values  
564 above 99%. The model was shown to hold for a 1.00ml syringe equipped with needles  
565 with inner diameters from 0.10mm up to 0.27mm and needle lengths from 10.0mm up  
566 to 50.0 mm and for Newtonian fluids with viscosities from 1.0mPas up to 4.3mPas.  
567 We have additionally presented a proof-of-concept for the system to log injection  
568 forces in an in vivo setting. The system and the present model can be used to pinpoint  
569 [geometrical and physical needle-syringe parameters in single needle perpendicular ID](#)  
570 [injection devices, controlling injection rate, viscosity, injection time and forces in](#)  
571 [function of intended application, usage and target group.](#)

Stijn Verwulgen 27/2/18 16:57

**Deleted:** that yields injection times and forces that are comfortable for both subjects and operators

Stijn Verwulgen 27/2/18 16:48

**Deleted:** needle geometry for intradermal injection devices.

577

578 **Conflict of interest**

579 Authors KB, VVK and SV are co-founders of Novosanis. The other  
580 authors report no potential conflict of interest.

581

582 **References**

- 583 1. Slominski A, Wortsman J, Paus R, Elias PM, Tobin DJ, Feingold KR. Skin as  
584 an endocrine organ: implications for its function. *Drug Discovery Today: Disease*  
585 *Mechanisms*. 2008;5(2):e137-e44.
- 586 2. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery  
587 systems transform vaccine administration? *Vaccine*. 2008;26(26):3197-208.
- 588 3. McGrath J, Uitto J. Anatomy and organization of human skin. *Rook's*  
589 *Textbook of Dermatology*, Eighth Edition. 2010:1-53.
- 590 4. Lai-Cheong JE, McGrath JA. Structure and function of skin, hair and nails.  
591 *Medicine*. 2009;37(5):223-6.
- 592 5. Young F, Marra F. A systematic review of intradermal influenza vaccines.  
593 *Vaccine*. 2011;29(48):8788-801.
- 594 6. Pileggi C, Lotito F, Bianco A, Nobile CG, Pavia M. Immunogenicity and  
595 safety of intradermal influenza vaccine in immunocompromized patients: a  
596 meta-analysis of randomized controlled trials. *BMC infectious diseases*.  
597 2015;15:427.
- 598 7. Vescovo P, Retty N, Ramaniraka N, Liberman J, Hart K, Cachemaille A, et  
599 al. Safety, tolerability and efficacy of intradermal rabies immunization with  
600 *DebioJect™*. *Vaccine*. 2017;35(14):1782-8.
- 601 8. Goswami A, Plun-Favreau J, Nicoloyannis N, Sampath G, Siddiqui MN,  
602 Zinsou J-A. The real cost of rabies post-exposure treatments. *Vaccine*.  
603 2005;23(23):2970-6.
- 604 9. McElhaney JE, Dutz JP. Better influenza vaccines for older people: what  
605 will it take? *The Journal of infectious diseases*. 2008;198(5):632-4.
- 606 10. Rosenfeld L. Insulin: discovery and controversy.. *Clinical chemistry*, .  
607 2002;48(12):2270-88.
- 608 11. Guy R. Transdermal science and technology-an update. *Drug Delivery*  
609 *System*. *Drug Delivery System*. 2007;22(4):442-9.
- 610 12. Norman JJ, Brown MR, Raviele NA, Prausnitz MR, Felner EI. Faster  
611 pharmacokinetics and increased patient acceptance of intradermal insulin  
612 delivery using a single hollow microneedle in children and adolescents with type  
613 diabetes. *Pediatric diabetes*. 2013;14(6):459-65.
- 614 13. Hickling J, & Jones, R. . Intradermal delivery of vaccines: a review of the  
615 literature and the potential for development for use in low-and middle-income  
616 countries. . 2009.
- 617 14. Tarnow K, King N. Intradermal injections: traditional bevel up versus  
618 bevel down. *Applied Nursing Research*. 2004;17(4):275-82.

Stijn Verwulgen 27/2/18 16:49

**Deleted:** Thus it can be assured that a given amount of fluid can be administered with forces and times that are comfortable for both subject and operator. .

- 623 15. Flynn PM, Sheneep, J. L., Mao, L., Crawford, R., Williams, B. F., & Williams, B.  
624 G. Influence of needle gauge in Mantoux skin testing. CHEST Journal.  
625 1994;106(5):1463-5.
- 626 16. Kim YC, Jarrahian C, Zehrung D, Mitragotri S, Prausnitz MR. Delivery  
627 systems for intradermal vaccination. Current topics in microbiology and  
628 immunology. 2012;351:77-112.
- 629 17. Larrañeta E, Lutton REM, Woolfson AD, Donnelly RF. Microneedle arrays  
630 as transdermal and intradermal drug delivery systems: Materials science,  
631 manufacture and commercial development. Materials Science and Engineering:  
632 R: Reports. 2016;104:1-32.
- 633 18. Lherould MS, Deleers M, Delchambre A. Hollow polymer microneedles  
634 array resistance and insertion tests. International journal of pharmaceutics.  
635 2015;480(1-2):152-7.
- 636 19. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon  
637 O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing  
638 intradermal influenza vaccination in healthy adults. Vaccine. 2009;27(3):454-9.
- 639 20. Hickling JK, Jones KR, Friede M, Zehrung D, Chen D, Kristensen D.  
640 Intradermal delivery of vaccines: potential benefits and current challenges.  
641 Bulletin of the World Health Organization. 2011;89(3):221-6.
- 642 21. Norman JJ, Gupta J, Patel SR, Park S, Jarrahian C, Zehrung D, et al.  
643 Reliability and accuracy of intradermal injection by Mantoux technique,  
644 hypodermic needle adapter, and hollow microneedle in pigs. Drug delivery and  
645 translational research. 2014;4(2):126-30.
- 646 22. Tsals I. Usability evaluation of intradermal adapters (IDA). Vaccine. 2016.
- 647 23. Laurent PE, Bonnet S, Alchas P, Regolini P, Mikszta JA, Pettis R, et al.  
648 Evaluation of the clinical performance of a new intradermal vaccine  
649 administration technique and associated delivery system. Vaccine.  
650 2007;25(52):8833-42.
- 651 24. Kis EE, Winter G, Myschik J. Devices for intradermal vaccination. Vaccine.  
652 2012;30(3):523-38.
- 653 25. Terumo. Innovating to Create Value through New Perspectives and  
654 Synthesis. 2016.
- 655 26. Van Mulder TJ, Verwulgen S, Beyers KC, Scheelen L, Elseviers MM, Van  
656 Damme P, et al. Assessment of acceptability and usability of new delivery  
657 prototype device for intradermal vaccination in healthy subjects. Human  
658 vaccines & immunotherapeutics. 2014;10(12):3746-53.
- 659 27. Pietzsch JB, Shluzas LA, Paté-Cornell ME, Yock PG, Linehan JH. Stage-gate  
660 process for the development of medical devices. Journal of medical devices.  
661 2009;3(2):021004.
- 662 28. Cilurzo F, Selmin F, Minghetti P, Adami M, Bertoni E, Lauria S, et al.  
663 Injectability evaluation: an open issue. AAPS PharmSciTech. 2011;12(2):604-9.
- 664 29. Allmendinger A, Mueller R, Schwab E, Chipperfield M, Huwyler J, Mahler  
665 HC, et al. Measuring tissue back-pressure--in vivo injection forces during  
666 subcutaneous injection. Pharmaceutical research. 2015;32(7):2229-40.
- 667 30. Burckbuchler V, Mekhloufi G, Giteau AP, Grossiord JL, Huille S, Agnely F.  
668 Rheological and syringeability properties of highly concentrated human  
669 polyclonal immunoglobulin solutions. European journal of pharmaceutics and  
670 biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische  
671 Verfahrenstechnik eV. 2010;76(3):351-6.

Koen Beyers 13/3/18 21:22  
Formatted: Dutch

- 672 31. Adler M. INJECTABLES-Challenges in the Development of Pre-filled  
673 Syringes for Biologics from a Formulation Scientist's Point of View. American  
674 Pharmaceutical Review. 2012;15(1):96.
- 675 32. Gupta J, Park SS, Bondy B, Felner EI, Prausnitz MR. Infusion pressure and  
676 pain during microneedle injection into skin of human subjects. Biomaterials.  
677 2011;32(28):6823-31.
- 678 33. Fry A. Injecting Highly Viscous Drugs. Pharmaceutical Technology.  
679 2014;38(11).
- 680 34. Bonds RS, Asawa A, Ghazi AI. Misuse of medical devices: a persistent  
681 problem in self-management of asthma and allergic disease. Annals of Allergy,  
682 Asthma & Immunology. 2015;114(1):74-6. e2.
- 683 35. Leoni G, Lyness A, Ginty P, Schutte R, Pillai G, Sharma G, et al. Preclinical  
684 development of an automated injection device for intradermal delivery of a cell-  
685 based therapy. Drug delivery and translational research. 2017;7(5):695-708.
- 686 36. Sadri R, Floryan J. Accurate evaluation of the loss coefficient and the  
687 entrance length of the inlet region of a channel. Journal of fluids engineering.  
688 2002;124(3):685-93.
- 689 37. Brown GO. The history of the Darcy-Weisbach equation for pipe flow  
690 resistance. Environmental and Water Resources History2003. p. 34-43.
- 691 38. Sutera SP, Skalak R. The history of Poiseuille's law. Annual Review of  
692 Fluid Mechanics. 1993;25(1):1-20.
- 693 39. Santos RGd, Figueiredo JR. Laminar elliptic flow in the entrance region of  
694 tubes. Journal of the Brazilian Society of Mechanical Sciences and Engineering.  
695 2007;29(3):233-9.
- 696 40. Idelchik I, Steinberg M, Malyavskaya G, Martynenko O. Handbook of  
697 Hydraulic Resistance1994.
- 698 41. Simpson TW, Maier JR, Mistree F. Product platform design: method and  
699 application. Research in Engineering Design. 2001;13(1):2-22.
- 700 42. Van Mulder T, de Koeijer M, Theeten H, Willems D, Van Damme P,  
701 Demolder M, et al. High frequency ultrasound to assess skin thickness in healthy  
702 adults. Vaccine. 2017;35(14):1810-5.
- 703 43. Salgame P, Gendas C, Collins L, Jones-Lopez E, Ellner JJ. Latent  
704 tuberculosis infection--Revisiting and revising concepts. Tuberculosis.  
705 2015;95(4):373-84.
- 706 44. Yamada S, Yamada Y, Tsukamoto Y, Tabata M, Irie J. A comparison study  
707 of patient ratings and safety of 32-and 34-gauge insulin pen needles. Diabetology  
708 International. 2016;7(3):259-65.
- 709 45. Li M, Tian X, Schreyer DJ, Chen X. Effect of needle geometry on flow rate  
710 and cell damage in the dispensing-based biofabrication process. Biotechnology  
711 progress. 2011;27(6):1777-84.
- 712 46. Martanto W, Baisch SM, Costner EA, Prausnitz MR, Smith MK. Fluid  
713 dynamics in conically tapered microneedles. AIChE Journal. 2005;51(6):1599-  
714 607.

Koen Beyers 13/3/18 21:22  
Formatted: Dutch

715